Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®)

Schizophrenia Research

Volumn 146, Issue 1-3, 2013, Pages 196-200

  Acosta, Francisco J ^a   Ramallo Fariña, Yolanda ^b,d   Bosch, Esperanza ^c   Mayans, Teresa ^d   Rodríguez, Carlos J ^d   Caravaca, Ana ^d  

^a Mental Health Research Program   (Spain)

^b Servicio Canario de Salud   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

Adherence; Dosing; Electronic monitoring; Medication Event Monitoring System; Nonadherence; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DRUG DOSE; DRUG DOSE REGIMEN; ELECTRONIC MONITORING; ELECTRONICS; EVENING DOSAGE; FEMALE; HAWTHORNE EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; MORNING DOSAGE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ELECTRONICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84875922722     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.02.016     Document Type: Article

References (30)

1. Acosta F.J., Bosch E., Sarmiento G., Juanes N., Caballero-Hidalgo A., Mayans T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr. Res. 2009, 107:213-217.
2. Amador X.F., Strauss D.H., Yale S.A., Flaum M.M., Endicott J., Gorman J.M. Assessment of insight in psychosis. Am. J. Psychiatry 1993, 150:873-879.
3. Ascher-Svanum H., Nyhuis A.W., Stauffer V., Kinon B.J., Faries D.E., Phillips G.A., Schuh K., Awad A.G., Keefe R., Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr. Med. Res. Opin. 2010, 26(10):2403-2410.
4. Byerly M., Fisher R., Whatley K., Holland R., Varghese R., Carmody T., Magouirk B., Rush A.J. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005, 133:129-133.
5. Byerly M.J., Nakonezny P.A., Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. North Am. 2007, 30:437-452.
6. Carroll C.L., Feldman S.R., Camacho F.T., Manuel J.C., Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J. Am. Acad. Dermatol. 2004, 51(2):212-216.
7. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 2001, 23(8):1296-1310.
8. Cuffel B., Alford J., Fischer E.P., Owen R. Awareness of illness in schizophrenia and outpatient treatment adherence. J. Nerv. Ment. Dis. 1996, 184:653-659.
9. Denhaerynck K., Steiger J., Bock A., Schäfer-Keller P., Köfer S., Thannberger N., De Geest S. Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients. Am. J. Transplant. 2007, 7(1):108-116.
10. Díaz E., Neuse E., Sullivan M.C., Pearsall H.R., Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry 2004, 65:354-360.
11. Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin. Ther. 1999, 21:1074-1090.
12. Gilmer T.P., Dolder D.R., Lacro J.P., Folsom D.P., Lindamer L., García P., Jeste D.V. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 2004, 161:692-699.
13. Horne R.E. Treatment perception and self-regulation. The Self-Regulation of Health and Illness Behaviour 2003, 138-153. Routledge, London. L.D. Cameron, H. Leventhal (Eds.).
14. Jeste S.D., Patterson T.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003, 63:49-58.
15. Kay S., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
16. Kruse W., Rampmaier J., Ullrich G., Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int. J. Clin. Pharmacol. Ther. 1994, 32:452-457.
17. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63:892-909.
18. Lee H., Kane I., Sereika S.M., Cho R.Y., Jolley C.J. Medication-taking behaviours in young adults with schizophrenia: a pilot study. J. Psychiatr. Ment. Health Nurs. 2011, 18(5):418-424.
19. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127(1-3):83-92.
20. Nakonezny P.A., Byerly M.J. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr. Res. 2006, 82:107-114.
21. Remington G., Kwon J., Collins A., Laporte D., Mann S., Christensen B. The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 2007, 90:229-237.
22. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002, 57:209-219.
23. Saini S., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care 2009, 15(6):e22-e33.
24. Sajatovic M., Velligan D.I., Weiden P.J., Valenstein M.A., Ogedegbe G. Measurement of psychiatric treatment adherence. J. Psychosom. Res. 2010, 69:591-599.
25. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P., Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46.
26. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J. Psychiatr. Pract. 2010, 16(1):34-45.
27. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008, 336(7653):1114-1117.
28. Wagner G.J., Ghosh-Dastidar B. Electronic monitoring: adherence assessment or intervention?. HIV Clin. Trials 2002, 3(1):45-51.
29. Wickström G., Bendix T. The "Hawthorne effect""-what did the original Hawthorne studies actually show?. Scand. J. Work Environ. Health 2000, 26(4):363-367.
30. Yang M., Barner J.C., Worchel J. Factors related to antipsychotic oversupply among Central Texas Veterans. Clin. Ther. 2007, 29(6):1214-1225.